CDA基因单核苷酸多态性对中晚期非小细胞肺癌接受吉西他滨化疗患者预后的影响

doi:10.13481/j.1671-587x.20160224

Abstract

Abstract:

Objective: To investigate the influence of single nucleotide polymorphisms(SNP) of cytidine deaminase(CDA) in the curative effect of gemcitabine, and to clarify the correlation of CDA SNP with the clinical prognosis of the advanced non-small cell lung cancer(NSCLC) patients.Methods: CDA 79A>C gene was detected by Sequenom Massarray Genotype System among 93 patients with advanced NSCLC who received chemotherapy of gemcitabine.The associations between CDA 79A>C polymorphisms and progression free survival(PFS) and overall survival(OS) were estimated using Kaplan-meier methods and Log-rank test for univariate analysis, and COX proportional hazards model was used for multivariate analysis.Results: There was no significant correlation between the CDA 79A>C SNPs with the clinical and pathological characteristics of NSCLC patients.The median PFS in the patients with wild genotype A/A was 9.3 months, while the median PFS in the patients with mutant genotype A/C and C/C was 11 months;there was no significant difference between them (P=0.061). The median OS in the patients with wild genotype A/A was 21.7 months, and the median OS of the patients with mutant genotype was 22.1 months;there was no significant difference between them (P=0.513).Conclusion: CDA 79A>C SNPs can prolong the PFS of the NSCLC patients, but it does not affect the OS of the patients.

Key words: lung neoplasms, cytidine deaminase, single nucleotide polymorphisms, chemotherapy, gemcitabine, prognosis

CLC Number:

R734.2

ZAO Hang, WANG XU, LI WEI. Influence of single nucleotide polymorphisms of CDA in prognosis of advanced non-small cell lung cancer patients treated with gemcitabine[J].Journal of Jilin University Medicine Edition, 2016, 42(02): 316-320.

References

[1] Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359-386.

[2] Jemal A,Siegel R,Ward E,et al.Cancer statistics,2007[J].CA Cancer J Clin,2007,57(1):43-66.

[3] Le Chevalier T,Scagliotti G,Natale R,et al.Efficacy ofgemcitabine plus platinum chemotherapy compared with otherplatinum containing regimens in advanced non-small-cell lung cancer:ameta-analysis of survival outcomes[J].Lung Cancer,2005,47(1):69-80.

[4] Azzoli CG,Baker S Jr,Temin S,et al.American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer[J].J Clin Oncol,2010,13(3):171-189.

[5] Schiller JH,Harrington D,Belani CP,et a1.Comparisonof four chemotherapy regimens for advanced non-small cell lung cancer[J].N Engl J Med,2002,346(2):92-98.

[6] Taylor JG,Choi EH,Foster CB,et al.Using genetic variation to study humandisease[J].Trends Mol Med,2001,7(11):507-512.

[7] Sugiyama E,Kaniwa N,Kim SR,et al.Pharmacokinetics of gemcitabinein Japanese cancer patients:the impact of a cytidine deaminase polymorphism[J].J Clin Oncol,2007,25(1):32-42.

[8] Tibaldi C,Giovannetti,Vasile E,et al.Correlation of CDA,ERCC1,and XPD polymorphisms with response and survivalin gemcitabine/cisplatin treated advanced non-small cell lung cancer patients[J].Clin Cancer Res,2008,14(6):1797-1803

[9] Eisenhauer EA,Therasse P,Bogaerts,et al.New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.

[10] Marsh S,Mallon MA,Goodfellow P,et al.Concordance of pharmacogenetic markers in germline and colorectal tumor DNA[J].Pharmacogenomics,2005,6(8):873-877.

[11] Teng YS,Anderson JE,Giblett ER. Cytidine deaminase:a new genetic polymorphism demonstrated in human granulocytes[J].Am J Hum Genet,1975,27(4):492-497.

[12] Kühn K,Bertling WM,Emmrich F.Cloning of a functional cDNA for human cytidine deaminase (CDD) and its use as a marker of monocyte/macrophage differentiation[J].Biochem Biophys Res Commun,1993,190(1):1-7.

[13] Laliberté J,Momparler RL.Human cytidine deaminase:purification of enzyme,cloning,and expression of its complementary DNA[J].Cancer Res,1994,54(20):5401-5407.

[14] Gilbert JA,Salavaggione OE,Ji Y,et al.Gemcita-bine pharmacogenomics:cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics[J].Clin Cancer Res,2006,12(6):1794-1803.

[15] Vincenzetti S,Mariani PL,Cammertoni N,et al.Isoenzymatic forms of human cytidine deaminase[J].Protein Eng Des Sel,2004,17(12):871-877.

[16] Xu J,Zhou Y,Zhang J,et al.High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation[J].Clin Chim Acta,2012,413(15/16):1284-1287.

[17] Zhou M,Ding YJ,Feng Y,et al.Association of xeroderma pigmentosum group D(Asp312Asn,Lys751Gln) and cytidine deaminase (Lys27Gln,Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine[J].Genet Mol Res,2014,13(2):3310-3318.

[18] Kirch HC,SchroderJ,Hoppe H,et al.Recombinant gene products of two natural variants of the humancytidine deaminase gene conferdifferent deamination rates of cytarabine in vitro[J].Exp Hematol,1998,26(5):421-425.

[19] Maring JG, Wachters FM,Slijfer M,et al.Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients:impact of the 79A>C cytidine deaminase polymorphism[J].Eur J Clin Pharmacol,2010,66(6):611-617.

Influence of single nucleotide polymorphisms of CDA in prognosis of advanced non-small cell lung cancer patients treated with gemcitabine

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	ZHU Guangwei, ZHENG Wei, HUANG Yongjian, HUA Jin, YANG Shugang, YE Jianxin. Expression of MyD88 in cancer tissue of patients with colorectal cancer and clinical significance [J]. Journal of Jilin University(Medicine Edition), 2018, 44(05): 1047-1051.
[2]	ZHANG Tao, ZHANG Guoming, YAN Fei, LIU Zheng, HUO Qiang. Values of evaluation of heart rate variability in major adverse cardiac events in patients with acute myocardial infarction after PCI [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 780-785.
[3]	MA Hongyun, ZHUANG Xinming, XU Weiguo, LIU Yi. Inhibitory effects of hyaluronic acid nanoparticles loading doxorubicin and cisplatin on allograft breast cancer in mice [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 243-248.
[4]	YU Yunhe, DU Ye, HAN Bing, LI Sijie, SONG Lelian, FAN Zhimin. Observation on curative effects of neoadjuvant chemotherapy for different subtypes of Luminal B breast cancer and analysis on its prognosis [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 356-362.
[5]	FAN Liwen, FU Tong, GU Lin, WU Di, JIA Hongyao, SONG Dong. Accessory breast cancer: A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 412-415.
[6]	LI Xiaoxia, SUN Yan, QU Rongfeng, REN Lishen, LI Yarong. Primary breast diffuse large B-cell lymphoma: A report of 3 cases and literature review [J]. Journal of Jilin University Medicine Edition, 2018, 44(01): 166-169.
[7]	DENG Ziliang, WANG Sen, LI Peng, XIE Kuilong, LI Shuxian, ZHOU Shixiong, HE Xiaozhou, CHEN Dong, GUO Hongsheng. Enhancement of IL-37 in chemosensitivity of cervical cancer HeLa cells to cisplatin [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 862-866.
[8]	SUN Huiying, Du Bo, YU Zhi, LIU Hongquan, YU Hong. Clinical analysis on sudden sensorineural hearing loss complicated with BPPV and literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 1025-1029.
[9]	LIU Xiangliang, JI Wei, LI Li, ZHAO Yinghua, JIA Lin, WANG Zhiqiang, CHEN Xiao, LI Wei. Lung adenocarcinoma treated by Erlotinib HCL Tablets and chemotherapy combined with bevacizumab after drug resistance:A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 1019-1024.
[10]	SU Junyan, LI Yingjin, XU Changyan. Influence of CD96 and CD71 expressions in surface of leukemia stem cells in therapeutic effects and prognosis of children with acute leukemia [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 776-781.
[11]	YANG Dongyang, LAI Xiaorong, LI Ying, MA Liyu, LUO Gang, LI Zijun, XU Fei, MA Dong. Influence of primary resection and KRAS gene mutation in prognosis of mild symptomatic patients with stage Ⅳ colorectal cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 805-811.
[12]	XIAO Yan, WANG Huan, WANG Shumin, GAO Ying. Lung cancer complicated with syndrome of inappropriate secretion of antidiuretic hormone:A report of 2 cases and literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(03): 643-645.
[13]	HAO Zheng, LIU Nan, WANG Lu, LI Dongyuan, ZHAO Conghai, LIU Weiming, CHEN Zhuo, ZHANG Jinnan. Comparison of clinical effects between hematoma aspiration surgery guided by stereotactic and simple positioning in treatment of patients with medium dose of hypertensive hemorrhage [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 130-134.
[14]	LI Xingxing, TAN Jingjin, JIANG Shan, WAHG Ke. Role of let-7 and HMGA2 in occurrence and development of lung cancer: Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1116-1125.
[15]	GU Sanwei, MA Hongshuang, ZHAO Ling, JIANG Zhenyu. Analysis on clinical characteristics of PM/DM combined with thyroid disease [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 999-1004.